FDA Approves Dawnzera: RNA-Targeting ASO Marks Paradigm Shift for Hereditary Angioedema

August 17, 2026

Liv Hospital Turkey

Overview

In August 2025, the FDA granted approval to Dawnzera (donidalorsen-azyh), a groundbreaking RNA-targeting antisense oligonucleotide (ASO) for hereditary angioedema (HAE). By specifically silencing prekallikrein (PKK) mRNA in the liver, Dawnzera prevents the overproduction of inflammatory mediators, addressing the disease’s root cause. This approval promises to significantly enhance patient quality of life and represents a major leap forward in rare disease management and the application of ASO technology.

In Depth

Background

Hereditary angioedema (HAE) is a debilitating rare genetic disorder marked by recurrent, severe swelling affecting various body parts, including the face, extremities, airways, and gastrointestinal tract. Airway edema, in particular, poses a life-threatening risk, profoundly impairing patients’ quality of life. Historically, HAE management has largely centered on treating acute attacks. However, a critical unmet need has persisted for therapies that address the disease’s underlying pathophysiology, offering a preventive approach rather than reactive management.

Key Findings

In August 2025, the U.S. Food and Drug Administration (FDA) granted approval to Dawnzera (donidalorsen-azyh), an RNA-targeting antisense oligonucleotide (ASO), representing a significant breakthrough in hereditary angioedema (HAE) treatment. This approval fulfills a critical unmet need for HAE patients by offering a therapy that directly targets the disease’s root cause. Dawnzera’s introduction marks a major milestone for the evolution of ASO technology and its increasing impact on rare disease therapeutics.

Dawnzera operates by precisely silencing the messenger RNA (mRNA) of prekallikrein (PKK) within the liver. Prekallikrein is a crucial precursor to an enzyme that plays a central role in the dysregulated production of bradykinin, the peptide responsible for triggering HAE attacks. By mitigating PKK mRNA levels, Dawnzera effectively suppresses the synthesis of the PKK protein. This prevents the abnormal activation of bradykinin, thereby reducing the frequency and severity of edema attacks in HAE patients. This targeted mechanism of action, directly addressing the core pathophysiological pathway of HAE, positions Dawnzera as a potentially highly effective, long-term preventive treatment.

This innovative therapy is poised to significantly alter the treatment paradigm for HAE patients, moving from reactive management to effective, long-term prevention of attacks. Beyond HAE, the success of ASO technology, as demonstrated by Dawnzera, is expected to catalyze the development of therapeutics for other rare genetic disorders and diseases where specific protein expression targeting is feasible. As real-world clinical experience with Dawnzera accumulates, further data on its long-term safety and efficacy will be crucial. This genetic-level intervention underscores the transformative potential of precision medicine in addressing rare diseases, fostering optimism for future therapeutic advancements.

Source: https://int.livhospital.com/drugs/dawnzera/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.